Connexin-32 — a protein found in small channels between nerve cells and involved in cell-to-cell communication — works to progress Parkinson’s disease by binding to alpha-synuclein and spreading toxic protein clumps throughout the brain, research suggests. The study, “Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in…
A Cleveland Clinic researcher is getting a $3 million grant from the National Institutes of Health (NIH) to study the long-term impact of high-intensity aerobic exercise on Parkinson’s disease progression. The five-year award goes to Jay Alberts, PhD, a staff member in the department of biomedical…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded Casma Therapeutics $370,000 to advance an innovative class of therapies aimed at slowing disease progression. The grant will promote the biotechnology company’s investigation into compounds that activate the calcium channel TRPML1 to accelerate autophagy…
UCB has announced the start of a Phase 1b clinical trial to evaluate the efficacy and safety of its therapeutic candidate UCB0599 for the treatment of Parkinson’s disease. This multicenter clinical trial will take place across the United States. Current treatments for Parkinson’s, which include…
Vitamin B12 can prevent the formation of and destroy alpha-synuclein aggregates in the brain, lowering their toxicity and potentially helping to alleviate Parkinson’s disease, according to a study. The study, “Vitamin B12 inhibits α-synuclein fibrillogenesis and protects against amyloid-induced cytotoxicity,” was published in the journal…
Chrysin, a chemical commonly found in plants, may ease behavioral, cognitive, and neurochemical changes in Parkinson’s disease, according to a mouse study. The study, “Chrysin protects against behavioral, cognitive and neurochemical alterations in a 6-hydroxydopamine model of Parkinson’s disease,” was published in Neuroscience Letters. Studies…
Measuring the amount of alpha-synuclein in tiny vesicles collected from blood serum may help diagnose early Parkinson’s and identify patients with different types of this disease. The study with that finding, “Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease,” was published…
The U.S Food and Drug Administration (FDA) has granted a Breakthrough Device designation to Amprion’s proprietary technology, Protein Misfolding Cyclic Amplification (PMCA) — a device that holds the potential to diagnose Parkinson’s disease at a much earlier stage than current diagnostic methods. If approved by the…
The American Parkinson Disease Association (APDA) recently hosted two groups of experts who assessed scientific projects vying for funding, and addressed diversity issues in Parkinson’s disease research and care. The organization met with its scientific advisory board (SAB) to decide which grant projects it will fund for the 2019-2020…
Patients with bipolar disorder appear to have a nearly seven times higher risk of developing Parkinson’s disease later in life, according to a nationwide study in Taiwan. The study, “Bipolar disorder and risk of Parkinson disease: A nationwide longitudinal study,” was published in the journal…
Get regular updates to your inbox.
